– CANADA, Victoria – Asep Medical Holdings Inc. (CSE: ASEP | OTC: SEPSF) today announced the appointment of Dr. Richard Heinzl to its board of directors, effective immediately.
“Having a world-class physician and entrepreneur on our board will assist our mission to address unmet medical needs in large unsatisfied markets associated with antibiotic failure. Richard will provide a strong medical and global perspective to the board,” said CEO and co-founder, Robert Hancock.
About Dr. Richard Heinzl
Dr. Heinzl is a physician, humanitarian, entrepreneur and author whose current focus is genomics, artificial intelligence and healthcare worldwide. Based in New York and Toronto, he is currently CEO of My Next Health Inc., a next-generation functional genomics company.
Earlier in his career, Dr. Heinzl was the founder of the Canadian chapter of Médecins Sans Frontières/Doctors Without Borders, which won the Nobel Peace Prize in 1999. Recently, he was Global Medical Director for WorldCare Inc., a Boston-based, Harvard-affiliated virtual medicine company. He graduated from McMaster University’s Michael G. DeGroote School of Medicine and completed postgraduate degrees related to global health at Harvard University and the University of Oxford. He is an Emeritus Fellow of the American College of Preventive Medicine. His work and travels have taken him to over 80 countries, and he speaks widely in North America and abroad. In 2000 he received an Honorary Doctorate (LLD) from his alma mater McMaster University and was named one of the “Hundred People Who Make a Difference” in Canada by Penguin Books. In September 2016, he received the Harvard T.H. Chan School of Public Health Alumni Award of Merit, the School’s highest award.
Dr. Heinzl said, “I am very honoured to be part of the Asep team under Bob Hancock’s visionary scientific leadership. It is truly exciting to see how biotechnologies have tremendous potential to shift the paradigm of human healthcare.”
About Asep Medical
Asep Medical Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.
For more information: https://asepmedical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.